越南6-8月龄婴儿接种AIK-C麻疹疫苗的免疫原性
一项队列研究纳入210名6-8月龄婴儿,评估越南生产的AIK-C麻疹疫苗(104.21 PFU/0.5 mL)的免疫原性与安全性。196对血清样本中,血清应答率为88.27%(95%CI:83.77-92.77%),GMT为511 mIU/mL(95%CI:688-880 mIU/mL),各年龄组无显著差异。局部疼痛和瘙痒发生率为3.8%,发热≥37.5°C发生率为6.7%,表明该疫苗对6-8月龄婴儿有效且安全。
要点
- AIK-C麻疹疫苗在6-8月龄婴儿中血清应答率达88.27%。
- 基线抗体<14 IU/mL者应答率91.8%,14-<60 mIU/mL者仅64.29%。
- 局部反应发生率3.8%,发热≥37.5°C发生率6.7%。
核心结论
- AIK-C麻疹疫苗对6-8月龄婴儿有效且安全,有助于减少未来疫情中麻疹相关死亡。
研究设计与样本
- 在越南开展队列研究,纳入210名6-8月龄婴儿,评估AIK-C麻疹疫苗(104.21 PFU/0.5 mL)的免疫原性和安全性。
- 获得196名受试者的配对血清样本,血清阳性定义为≥120 mIU/mL。
主要发现
- 血清应答率为173/196(88.27%,95%CI:83.77-92.77%),GMT为511 mIU/mL(95%CI:688-880 mIU/mL),不同年龄组间无显著差异。
- 基线<14 IU/mL组血清应答率为112/122(91.8%,95%CI:86.94-96.67%),GMT为597 mIU/mL(95%CI:749-1002 mIU/mL)。
- 基线14-<60 mIU/mL组血清应答率为18/28(64.29%),GMT为184 mIU/L,显著低于<14 mIU/mL组(p<0.01)。
- 16名基线血清阳性者全部出现血清转化(较接种前升高4倍),GMT为1078 mIU/mL。
- 接种后7天内局部疼痛和瘙痒发生率为8/210(3.8%),发热≥37.5°C发生率为14/210(6.7%)。
临床怎么用
- 对于6-8月龄婴儿,尤其是麻疹疫情暴发期间,可考虑接种AIK-C麻疹疫苗以提供保护。
- 接种前基线抗体水平可能影响血清应答率,需关注低基线抗体者的免疫效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Measles-associated deaths have been reported in infants <9 months during outbreaks. A cohort study was conducted on 210 infants aged 6-8 months to evaluate the immunogenicity and safety of the AIK-C measles vaccine containing 104.21 plaque-forming units (PFU)/0.5 mL produced in Vietnam. Paired serum samples were obtained from 196 subjects. Seropositivity was defined as ≥120 mIU/mL. The seroresponse rate was 173/196 (88.27%, 95% confidence interval (CI): 83.77-92.77%) with geometric mean titer (GMT) of 511 mIU/mL (95% CI: 688-880 mIU/mL), and no significant differences were observed by different age groups. Among 196 paired sera, they were categorized into four groups: 122 subjects <14 IU/mL, 28 subjects 14-<60 mIU/mL, 30 subjects 60-<120 mIU/mL, and 16 subjects ≥ 120 mIU/mL. The seroresponse rate was 112/122 (91.8%, 95% CI: 86.94-96.67%) with GMT (597 mIU/mL, 95% CI: 749-1002 mIU/mL) in the <14 mIU/L group. In the 14-<60 mIU/mL group, the seroresponse rate was 18/28 (64.29%) with 184 mIU/L of GMT and was significantly lower (p < 0.01) than that in the <14 mIU/mL group. In the 16 seropositive group, all subjects showed seroconversion (4-fold higher than before) with a higher GMT of 1078 mIU/mL. Local pain and itching at the injection site were observed in 8 subjects (3.8%) within 7 days of the vaccination. Regarding systemic adverse reactions, febrile illness ≥37.5 °C was observed in 14 subjects (6.7%). These results indicate that the AIK-C measles vaccine is effective and safe for infants aged 6-8 months and will contribute to reducing the number of measles-associated deaths in future outbreaks.
引用
- Hong DT, Hien ND, Thao PTP, et al. Immunogenicity of the AIK-C measles vaccine in infants aged <9 months in Vietnam. Vaccine. 2019. PMID: 31174936. doi:10.1016/j.vaccine.2019.04.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。